Mankind Pharma Ltd. net profit rose 31.7% at Rs 554 crore in the fourth quarter of the previous fiscal. This is in comparison to profit of Rs 421 crore in the fourth quarter of fiscal 2025, according to its stock exchange notification on Tuesday.
Consolidate revenue of the pharma company advanced by 11.8% year-on-year for the three months ended March, reaching Rs 3,443 crore in comparison to Rs 3,079 crore. Operating income, or earnings before interest and taxes rose 36.1% to Rs 930 crore from Rs 683 crore. Margins expanded to 27% from 22.2% in the same quarter of fiscal 2025.
Mankind Pharma Q4 Result Highlights (Cons, YoY)
- Net Profit up 31.7% at Rs 554 crore versus Rs 421 crore
- Revenue up 11.8% at Rs 3,443 crore versus Rs 3,079 crore
- Ebitda up 36.1% at Rs 930 crore versus Rs 683 crore
- Ebitda Margin at 27% versus 22.2%
- Appoints Satish Kumar Sharma as Whole-Time Director for 5 years
- To invest Rs 500 crore more in arm Mankind Medicare
ALSO READ: BPCL Q4 Results: One-Time Loss Drags Profit Down 58%, Revenue Remains Flat
Mankind Pharma also approved plan to invest Rs 500 crore in its arm Mankind Medicare. The board also appointed Satish Kumar Sharma as the whole-time director for five years.
Mankind Pharma Share Price Today
The earnings were announced after market close on Tuesday. The scrip closed 0.12% lower at Rs 2,492.6 apiece, this compares to a 0.14% decline in the NSE Nifty 50 index. During the day, the stock fell as much as 1.03% to Rs 2,470 per share.
It has fallen 2.79% in the last 12 months and risen 13.48% year-to-date.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
